The Defense Health Agency awarded a $82.8K firm fixed-price purchase order to Cerus Corporation on February 7, 2020, for maintenance services on two illuminators used in the INTERCEPT Blood System. The contract, which includes a base year plus four option years, is scheduled for completion by February 8, 2025, with performance occurring at a location in Japan. This award was not set-aside for small businesses or other designated categories. Cerus Corporation, a biomedical products manufacturer headquartered in Concord, California, specializes in blood safety technologies and pathogen reduction systems, with the INTERCEPT Blood System representing its core proprietary offering that uses riboflavin and ultraviolet light to inactivate pathogens in blood components.
This maintenance contract reflects the Defense Health Agency's continued investment in blood safety infrastructure across military medical facilities. As a sole-source award, the contract demonstrates Cerus Corporation's unique technological capabilities and established relationship with DHA for supporting pathogen-reduced blood products at military healthcare installations. The company's contract history with the agency includes procurement of INTERCEPT processing sets, storage containers, and maintenance services at various naval hospitals and military medical centers, positioning this award as part of broader efforts to reduce transfusion-transmitted infections and enhance medical readiness within the military healthcare system.